Freedom to Operate
Analysis of whether a product can be sold without infringing third-party IP.
Definition
An FTO analysis identifies in-force third-party patent claims that could be infringed by a planned product, and assesses design-around or licensing options. Distinct from patentability - a company can have its own patent and still infringe another.What this means in practice
Investor and acquirer DD requires clean FTO opinions. Late-stage FTO surprises can derail financings and M&A.Examples
- A startup developing a novel surgical robot conducts an FTO analysis to ensure its mechanical design and software algorithms do not infringe existing patents held by larger medical device companies.
- Before launching a new diagnostic assay, a laboratory performs an FTO search to confirm that its reagents and testing methodology do not violate any in-force third-party patent claims.
- A manufacturer planning to introduce a next-generation implantable device reviews the FTO landscape to identify potential infringement risks related to materials science or manufacturing processes.
- •Failing to conduct FTO analysis early in the product development lifecycle can lead to significant redesigns, delays, or even project cancellation.
- •Assuming that obtaining your own patent guarantees freedom to operate is a common and dangerous misconception, as separate patents may exist that cover aspects of your device.
- •Neglecting to update FTO analyses throughout the product lifecycle as new patents are granted or product designs evolve can expose a company to infringement risks.
- •Relying solely on in-house legal opinions without seeking external expert review for complex FTO assessments can lead to overlooked risks.
- •Ignoring FTO for software components or ancillary devices that integrate with the main MedTech product can create unexpected legal vulnerabilities.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsFounder & Investor Primer
· From this learning pathFDA program providing expedited review for devices that treat life-threatening or irreversibly debilitating conditions.
Sequential priced equity rounds in venture-backed companies, typically progressing from product-market validation (A) to scale (B) to growth (C+).
Market sizing framework: total, serviceable available, and serviceable obtainable.
FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
More in Commercialization
· Same categoryIndustry code governing interactions between U.S. medical-device companies and healthcare professionals.
Convening of external experts to advise on strategy or product.
U.S. criminal statute prohibiting remuneration to induce federal healthcare business.
Primary references
3 sources- 1
USPTO patent basicsVerifiedUSPTOuspto.gov
- 2
AHRMM - Healthcare Supply ChainVerifiedAHRMMahrmm.org
- 3
AdvaMed Code of EthicsVerifiedAdvaMedadvamed.org
Inline markers like [1] jump to the matching reference above.